4.6 Article

Stress response symptoms in adolescents during the first year after a parent's cancer diagnosis

Journal

SUPPORTIVE CARE IN CANCER
Volume 18, Issue 11, Pages 1421-1428

Publisher

SPRINGER
DOI: 10.1007/s00520-009-0764-6

Keywords

Stress response symptoms; Adolescents; Parental cancer; Longitudinal

Funding

  1. Dutch Cancer Society [2000-2333]

Ask authors/readers for more resources

Purpose This work aims to prospectively study stress response symptoms (SRS) in adolescents during the first year after a parent's cancer diagnosis and factors associated with SRS. Additionally, SRS in these adolescents were compared to SRS in adolescents whose parents were diagnosed 1-5 years (reference group) previously. Methods Forty-nine adolescents, 37 ill parents, and 37 spouses completed questionnaires within 4 months after diagnosis (T1) and six (T2) and 12 months (T3) later. Results Clinically elevated SRS were found in 29% of adolescents at T1,16% at T2, and 14% at T3. In contrast, in the reference group, we found 29% clinically elevated SRS. Daughters seemed more at risk than sons. Adolescents' age, patient's gender, and intensity and duration of treatment did not significantly affect SRS. Adolescents with more SRS reported having more emotional/behavioral problems. Parents observed fewer problems in those adolescents. Initial SRS affected later SRS and emotional problems. Conclusions The findings illustrate that adolescent children of cancer patients may have clinically elevated SRS that are associated with emotional and behavioral problems. The prevalence of such problems may be underestimated by the parents.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Psychosocial consequences of surviving cancer diagnosed and treated in childhood versus in adolescence/young adulthood: A call for clearer delineation between groups

Anne-Sophie E. Darlington, Claire E. Wakefield, Loes M. E. van Erp, Winette T. A. van der Graaf, Richard J. Cohn, Martha A. Grootenhuis

Summary: Survivors of childhood cancer and survivors of cancer in adolescence or young adulthood may experience similar and different psychosocial issues, and it is necessary to have a clearer delineation for these two groups.

CANCER (2022)

Article Oncology

First-line chemotherapy in advanced intrabdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis

Silvia Stacchiotti, Winette T. A. Van der Graaf, Roberta G. Sanfilippo, Sandrine Marreaud, Winan J. Van Houdt, Ian R. Judson, Alessandro Gronchi, Hans Gelderblom, Saskia Litiere, Bernd Kasper

Summary: This retrospective analysis of first-line chemotherapy in intra-abdominal liposarcoma found that anthracycline-based chemotherapy had limited efficacy, while regimens containing ifosfamide showed higher activity, although not statistically significant in a small number of cases. The study provides a benchmark for future trials on new drugs in well-differentiated/dedifferentiated liposarcoma.

CANCER (2022)

Review Oncology

Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature

Deborah van de Wal, Mai Elie, Axel Le Cesne, Elena Fumagalli, Dide den Hollander, Robin L. Jones, Gloria Marquina, Neeltje Steeghs, Winette T. A. van der Graaf, Olga Husson

Summary: This study systematically reviews the HRQoL issues and side effects of different TKIs registered for the treatment of GIST. The results show that most patients maintained stable HRQoL during TKI therapy, but patients treated with sunitinib reported a decrease in HRQoL. Severe fatigue and fear of recurrence or progression negatively impacted overall HRQoL.

CANCERS (2022)

Review Oncology

Clinical trials in desmoid-type fibromatosis in children and adults: A systematic review

Simone A. van Maren, Max M. van Noesel, Olga Husson, Winette T. A. van der Graaf

Summary: Desmoid-type fibromatosis (DTF) is a rare and locally aggressive tumor, with an increasing incidence as age grows. For most patients, DTF is a chronic and symptomatic disease that impacts their quality of life. The treatment approaches for DTF patients differ between pediatric oncologists and medical oncologists, mainly due to the accessibility of certain drugs in pediatric oncology. Additionally, there is a lack of research on patient-reported outcomes, which is crucial for patients with chronic diseases like DTF.

PEDIATRIC BLOOD & CANCER (2022)

Article Oncology

AYAs' online information and eHealth needs: A comparison with healthcare professionals' perceptions

Danielle L. van de Graaf, Carla Vlooswijk, Nadine Bol, Emiel J. Krahmer, Rhode Bijlsma, Suzanne Kaal, Sophia H. E. Sleeman, Winette T. A. van der Graaf, Olga Husson, Mies C. van Eenbergen

Summary: Adolescents and young adults diagnosed with cancer often rely on the Internet for cancer-related information, but healthcare professionals' perceptions of their needs may not align with their actual needs. A survey found discrepancies between AYAs' online information and eHealth needs and HCPs' perceptions, highlighting the potential for insufficient guidance.

CANCER MEDICINE (2023)

Article Oncology

Unraveling Desmoid-Type Fibromatosis-Specific Health-Related Quality of Life: Who Is at Risk for Poor Outcomes

Anne-Rose W. Schut, Emma Lidington, Milea J. M. Timbergen, Eugenie Younger, Winette T. A. van der Graaf, Winan J. van Houdt, Johannes J. Bonenkamp, Robin L. Jones, Dirk J. Grunhagen, Stefan Sleijfer, Cornelis Verhoef, Spyridon Gennatas, Olga Husson

Summary: Desmoid-type fibromatosis (DTF) is a rare soft tissue tumor that significantly impacts the health-related quality of life (HRQoL) of patients. This study evaluated HRQoL among different groups of DTF patients and identified factors such as age, sex, presence of comorbidities, and treatment type that were associated with DTF-specific HRQoL.

CANCERS (2022)

Article Oncology

Correlation of radiological and histopathological response after neoadjuvant radiotherapy in soft tissue sarcoma

Sophie J. M. Reijers, Nicolo Gennaro, Annemarie Bruining, Hester van Boven, Petur Snaebjornsson, Elise M. M. Bekers, Frits van Coevorden, Astrid N. N. Scholten, Yvonne Schrage, Winette T. A. van der Graaf, Rick L. M. Haas, Winan J. J. van Houdt

Summary: This study aimed to assess the association between radiological and histopathological response after neoadjuvant radiotherapy in soft tissue sarcoma, and the prognostic value of different response evaluation methods. The results showed that radiological response was not significantly associated with survival rates, while only necrosis in histopathological parameters was associated with overall survival.

ACTA ONCOLOGICA (2023)

Editorial Material Oncology

EORTC is 60-and far from contemplating retirement

Winette Van der Graaf, Denis Lacombe

EUROPEAN JOURNAL OF CANCER (2023)

Article Oncology

Impaired social functioning in adolescent and young adult (AYA) sarcoma survivors: Prevalence and risk factors

Cas Drabbe, Elena S. Coenraadts, Winan J. van Houdt, Michiel A. J. van de Sande, Johannes J. Bonenkamp, Jacco J. de Haan, Johanna W. M. Nin, Cornelis Verhoef, Winette T. A. van der Graaf, Olga Husson

Summary: This study aims to identify AYA sarcoma survivors with impaired social functioning (ISF) and determine the clinical and psychosocial factors associated with ISF. The study found that more than one-quarter of AYA sarcoma survivors experience ISF long after diagnosis. Unemployment and having to make lifestyle changes due to financial problems caused by physical conditions or medical treatment were associated with ISF, while better social support was associated with non-ISF. These results emphasize the importance of follow-up care that focuses not only on the disease but also on the psychological and social domains.

CANCER (2023)

Article Oncology

The patient's perspective on side effects of tyrosine kinase inhibitors in the treatment of advanced and metastatic gastrointestinal stromal tumors

Deborah van de Wal, Shreenila Venkatesan, Charlotte Benson, Winette T. A. van der Graaf, Colin D. Johnson, Olga Husson, Samantha C. Sodergren

Summary: The aim of this study was to explore the side effects of tyrosine kinase inhibitors on gastrointestinal stromal tumor patients from the patient's perspective, and compare it with the perspective of healthcare professionals. Semi-structured interviews were conducted with 19 advanced or metastatic gastrointestinal stromal tumor patients, and a focus group was held with five patients and six healthcare professionals. Thematic analysis revealed that most participants reported gastrointestinal symptoms, tiredness, edema, muscle cramps, skin problems, eye problems, and trouble sleeping. Patients, but not healthcare professionals, reported cognitive problems or symptoms of depression. These findings highlight the importance of including the patient's perspective in symptom reporting.

FUTURE ONCOLOGY (2023)

Article Oncology

Financial outcomes of adolescent and young adult cancer survivors: a longitudinal population-based registry study

Ties M. Siebinga, Silvie H. M. Janssen, Anke W. Boumans, Mies C. Van Eenbergen, Bettina Siflinger, Winette T. A. Van der Graaf, Olga Husson

Summary: This study explored the long-term income patterns and determinants among adolescent and young adult (AYA) cancer survivors, and compared them with their peers. It was found that, on average, AYA cancer survivors experience an 8.5% decrease in annual earnings compared to the control group. Younger age, marriage, female gender, diagnosis of stage IV disease, and central nervous system cancer were associated with the largest decline in income.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

Article Oncology

Physical symptom burden in patients with desmoid-type fibromatosis and its impact on health-related quality of life and healthcare use

Anne-Rose W. Schut, Leanne E. de Bruin, Belle H. de Rooij, Emma Lidington, Milea J. M. Timbergen, Winette T. A. van Der Graaf, Winan J. van Houdt, Johannes J. Bonenkamp, Robin L. Jones, Dirk. J. Gruenhagen, Stefan Sleijfer, Spyridon Gennatas, Cornelis Verhoef, Olga Husson

Summary: By studying the level of symptom burden, DTF patients can be categorized into four subgroups, with patients in the high symptom burden subgroup having poorer health-related quality of life and higher healthcare utilization. Understanding the symptom burden of DTF patients can help identify high-risk patients and tailor supportive care to individual needs.

CANCER MEDICINE (2023)

Review Oncology

Caring for Adolescents and Young Adults (AYA) with Cancer: A Scoping Review into Caregiver Burdens and Needs

Milou J. P. Reuvers, Asiye Gedik, Kirsty M. Way, Sanne M. van de Stadt, Winette T. A. van der Graaf, Olga Husson

Summary: This review provides an overview of the impact of being a caregiver for an AYA cancer patient on different domains of their lives and reports the unmet needs they identify. By being more attentive to the caregivers and intervening accordingly, caregivers' quality of life can increase, resulting in better caregiving capabilities. This not only benefits the patient but also decreases caregiver burden.

CANCERS (2023)

Letter Medicine, General & Internal

Desmoid is not a sarcoma; reply to Sachdev et al.

Winette T. A. van der Graaf, Olga Husson, Winan J. van Houdt

ECLINICALMEDICINE (2023)

Article Oncology

Therapeutic drug monitoring to personalize dosing of imatinib, sunitinib, and pazopanib: A mixed methods study on barriers and facilitators

Kim Westerdijk, Neeltje Steeghs, Casper S. J. Tacke, Winette T. A. van der Graaf, Nielka P. van Erp, Gerard van Oortmerssen, Rosella P. M. G. Hermens, Ingrid M. E. Desar, DPOG

Summary: Personalized dosing based on drug level measurement and adjustment can improve efficacy and reduce toxicity in oncological treatment. However, the use of therapeutic drug monitoring (TDM)-guided dosing for imatinib, sunitinib, and pazopanib is not widely adopted, despite evidence supporting individualized dosing.

CANCER MEDICINE (2023)

No Data Available